Is there an approved drug containing interleukin‑15 (IL‑15) for cancer prevention?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No FDA-Approved IL-15 Drug for Cancer Prevention Exists

There is currently no FDA-approved drug containing interleukin-15 (IL-15) specifically for cancer prevention. IL-15-based therapies are being developed and tested exclusively for cancer treatment, not prevention.

Current Status of IL-15 in Cancer Therapy

FDA-Approved IL-15 Therapy

  • Nogapendekin alfa inbakicept (N-803) is the only FDA-approved IL-15-based immunotherapy, but it is indicated for treating existing cancer, not preventing it 1.

Clinical Development Focus

IL-15 therapies are being investigated in multiple clinical trials for cancer treatment in patients with established malignancies:

  • Recombinant human IL-15 (rhIL-15) has been tested in patients with metastatic melanoma and renal cell cancer, showing immune activation but requiring dose optimization due to toxicities including hypotension, thrombocytopenia, and liver enzyme elevations 2
  • Combination trials are ongoing with checkpoint inhibitors (IL-15 + nivolumab + ipilimumab, NCT03388632), monoclonal antibodies (IL-15 + alemtuzumab for ATL, NCT02689453; IL-15 + obinutuzumab for CLL, NCT03759184), and other immunotherapies 3

Why IL-15 Is Not Used for Prevention

IL-15 is a potent immunostimulatory cytokine that causes:

  • Massive expansion of NK cells (up to 50-fold) and CD8+ T cells 2
  • Significant inflammatory cytokine release (up to 50-fold increases in serum inflammatory markers) 2
  • Dose-limiting toxicities even at therapeutic doses 2

These properties make IL-15 unsuitable for cancer prevention in healthy individuals, where the risk-benefit ratio would be unacceptable.

Important Distinction: Treatment vs. Prevention

The evidence consistently shows IL-15 is being developed as:

  • Therapeutic agent for patients with active cancer 3, 2, 1
  • Adjunct to other cancer treatments like checkpoint inhibitors and CAR-T cells 1
  • Component of tumor-infiltrating lymphocyte (TIL) therapy where it supports immune cell expansion after tumor resection 4

No clinical trials or regulatory pathways exist for IL-15 as a cancer prevention agent in healthy populations.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.